Welcome to our dedicated page for Eledon Pharmaceuticals news (Ticker: ELDN), a resource for investors and traders seeking the latest updates and insights on Eledon Pharmaceuticals stock.
Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) is a clinical stage biotechnology company developing immune-modulating therapies centered on the CD40 Ligand (CD40L) pathway. The company’s news flow largely reflects progress with its lead investigational product, tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand that Eledon describes as having broad therapeutic potential.
News updates for ELDN commonly cover clinical trial milestones in kidney allograft transplantation, islet cell transplantation, xenotransplantation and amyotrophic lateral sclerosis (ALS). For example, Eledon has issued press releases on Phase 2 BESTOW trial results in de novo kidney transplant recipients, highlighting kidney function outcomes, safety and tolerability compared with tacrolimus-based regimens. Additional announcements have detailed updated data from a Phase 1b open-label kidney transplant study and long-term extension work.
Another recurring theme in Eledon’s news is the use of tegoprubart in islet transplantation for individuals with type 1 diabetes. The company has reported preliminary results from an investigator-initiated trial at the University of Chicago Medicine’s Transplant Institute, describing insulin independence and improved glycemic control in the first treated subjects. Eledon also issues updates on tegoprubart’s role in xenotransplantation, including its use as a key component of immunosuppression regimens in pig-to-human kidney transplant procedures at Massachusetts General Hospital.
Investors following ELDN news can also expect announcements related to scientific conference presentations, participation in healthcare conferences, financing transactions such as underwritten public offerings of common stock and pre-funded warrants, and selected financial results. This news page aggregates such disclosures so readers can review Eledon’s reported clinical data, corporate developments and regulatory-related communications over time.
Eledon Pharmaceuticals (Nasdaq: ELDN) summarized 2025 progress and provided a 2026 outlook centered on tegoprubart development across kidney allotransplantation, islet transplantation and xenotransplantation. Key 2025 results: Phase 2 BESTOW showed a mean eGFR of 69 mL/min/1.73 m² (n=51) at 12 months and demonstrated non-inferiority versus tacrolimus on an efficacy-failure composite (22.2% vs. 17.2% using a 20% non-inferiority margin). Investigator-led islet transplants (UChicago) reported insulin independence in the first six patients. Tegoprubart was used in four pig-to-human xenotransplants (three at MGH). The company completed a $57.5 million financing, expected to fund operations into 2Q 2027. Anticipated 2026 milestones include FDA guidance on Phase 3 design and multiple long-term data readouts.
Eledon Pharmaceuticals (Nasdaq: ELDN) announced that CEO David-Alexandre C. Gros, M.D. will participate in a fireside chat at the 37th Annual Piper Sandler Healthcare Conference on Thursday, December 4, 2025 at 8:50 a.m. ET (5:50 a.m. PT).
The session will be available via live webcast with a replay accessible on the company website under Events for registered attendees.
Eledon (NASDAQ: ELDN) reported preliminary results from the first six type 1 diabetes patients in an investigator-initiated islet transplant trial using tegoprubart as the core tacrolimus-free immunosuppressant.
All six subjects achieved and maintained insulin independence after one or two transplants; three patients have been insulin-free >15 months, one reached HbA1c 4.7% for >15 months, two patients reached insulin independence ≈4 weeks post-transplant with HbA1c <6% for >3 months, and a sixth is insulin-free with HbA1c 5.3%. No serious infections, thromboembolic events, rejection events, or kidney/neurologic toxicities were reported.
Eledon Pharmaceuticals (Nasdaq: ELDN) reported Q3 2025 results and business highlights on Nov 14, 2025. Key points: Phase 2 BESTOW data showed tegoprubart with a favorable safety profile and an eGFR of approximately 69 mL/min/1.73m2 at 12 months in the treatment arm (n=51), supporting plans to advance to Phase 3 after regulator discussions. The company completed an underwritten public offering on Nov 13, 2025, raising $57.5 million gross (net ≈ $53.6M) to fund transplantation programs. Cash and short-term investments were $93.4 million as of Sept 30, 2025. Anticipated 2026 milestones include FDA guidance and initiation of a Phase 3 kidney transplant trial.
Eledon Pharmaceuticals (NASDAQ: ELDN) priced an underwritten public offering on Nov 12, 2025 to raise approximately $50 million gross. The offering includes 15,152,485 shares of common stock at $1.65 per share and, in lieu of common stock to certain investors, 15,151,515 pre-funded warrants at $1.649 each; the pre-funded warrants are immediately exercisable at $0.001 per share. Eledon granted underwriters a 30-day option to purchase up to 4,545,600 additional shares. The offering is expected to close on or about Nov 13, 2025, with net proceeds intended to support clinical development and general corporate purposes.
Eledon Pharmaceuticals (NASDAQ: ELDN) announced an underwritten public offering of shares of common stock and, for certain investors, pre-funded warrants to purchase common stock.
The company will grant underwriters a 30-day option to buy up to 15% additional shares (overallotment). The offering is subject to market and other conditions and may not be completed. Leerink Partners and Cantor are joint book-running managers.
Eledon intends to use net proceeds to support continued clinical development of product candidates, advance pipeline programs, and for general corporate purposes. The offering is made under a Form S-3 registration (File No. 333-282260) declared effective October 2, 2024, with a preliminary prospectus supplement to be filed with the SEC.
Eledon (NASDAQ: ELDN) reported Phase 2 BESTOW results for tegoprubart in kidney transplantation presented at ASN Kidney Week on November 6, 2025.
In a 127-patient randomized trial (tegoprubart n=63, tacrolimus n=64) tegoprubart produced a 12-month mean eGFR ≈69 mL/min/1.73 m² vs 66 mL/min/1.73 m² for tacrolimus, showed non-inferiority on the FDA composite efficacy-failure endpoint (22% vs 17% using a 20% margin), and demonstrated substantially lower rates of new-onset diabetes, tremor, delayed graft function and some cardiovascular events. Cash was ~$93.4M at 9/30/2025, funding operations into late 2026.
Eledon Pharmaceuticals (Nasdaq: ELDN) will present at the Guggenheim Second Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 10:30 a.m. ET (7:30 a.m. PT). David-Alexandre C. Gros, M.D., CEO, will deliver the presentation. A live webcast will be available with a replay posted on the company website under Events for registered users.
Eledon Pharmaceuticals (Nasdaq: ELDN) announced an oral presentation of topline results from the Phase 2 BESTOW trial of tegoprubart for prevention of rejection in kidney transplantation at ASN Kidney Week 2025 in Houston on November 6, 2025.
The presentation by Andrew Adams, M.D., Ph.D. is scheduled for 5:30–5:42 p.m. CT in Grand Ballroom C. A conference call to discuss the results will be held on November 7, 2025 at 8:00 a.m. ET with a live webcast on the company investor site; the webcast will be archived after the call.
Eledon Pharmaceuticals (Nasdaq: ELDN) announced that its President and Chief Scientific Officer, Steve Perrin, Ph.D., will present at the 18th Congress of the International Xenotransplantation Association (IXA) in Geneva, Switzerland. The presentation will take place on October 1, 2025, from 10:30 a.m. to 12:00 p.m. CET during a plenary session focused on immunosuppression and anti-CD154 pathway blockade.
FAQ
What is the current stock price of Eledon Pharmaceuticals (ELDN)?
What is the market cap of Eledon Pharmaceuticals (ELDN)?
